Omnihealth Practice Presents

NOW APPROVED FOR

WEIGHT MANAGEMENT1

*Hypothetical patient

Mounjaro®, a single molecule activating both GIP and GLP-1 receptors, helped patients achieve significant mean weight loss at 16.0% - 22.5% at 72 weeks.1,2,†,‡

Meet Andrea*

She is living with obesity or overweight and a weight-related complication^

  • She has tried diet and exercise multiple times, yet has been unsuccessful at losing weight and maintaining it
  • She is worried about her excess weight and risk of weight related complications^
  • She is starting to feel the emotional and physical burden of excess weight in her daily life

*Hypothetical patient profile

Why do people with obesity, like Andrea*, need help?

People like Andrea* face physiological barriers our of their control when striving to lose weight and maintain it4

Image 1 Image 2 Image 3
Due to metabolic and endocrine adaptations, lifestyle modifications alone may not be enough to maintain weight loss, putting people like Andrea* at risk for weight-related complications4,5,^

*Hypothetical patient profile

†Studied in adults with obesity (BMI of ≥30 kg/m2) or overweight (BMI of ≥27 kg/m2) with at least one weight-related complication, excluding T2D.2 All participants received lifestyle interventions, including a reduced-calorie diet and increased physical activity. 2

‡p<0.001 vs baseline. Mean % change in weight vs baseline (co-primary endpoint) at 72 weeks was -16.0% and -21.4% for the 5 mg and 10 mg doses respectively. Mean % change in weight vs placebo at 72 weeks was -13.5%, -18.9%, -20.1% for the 5 mg, 10 mg and 15 mg doses respectively (p<0.001 vs placebo, adjusted for multiplicity). 1,2

^Examples include hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus1

BMI = body mass index; GIP = Glucose-dependent insulinotropic polypeptide; GLP-1 = glucagon-like peptide-1; T2D = type 2 diabetes

  1. Mounjaro® Hong Kong Prescribing Information
  2. Jastreboff AM, et al. N Engl J Med. 2022;387(3):205-16 (+Suppl. Appendix).
  3. Sumithran P, et al. N Engl J Med. 2011;365(17):1597-604.
  4. Hall KD, Kahan S. Med Clin North Am. 2018;102(1):183-97.
  5. Bray GA, et al. Obes Rev. 2017;18(7):715-23.

How can Mounjaro® help people with obesity achieve their weight loss goals?

Mounjaro® is the first and only GIP and GLP-1 receptor agonist approved for weight management1,2

The role of GIP and GLP-1 receptors in the physiology of weight management1,3-8

GIP and GLP-1 receptors are present in many body areas, including brain regions that regulate appetite1,†

GIP receptors are also present in adipose tissue and help regulate fat storage1,3

GLP-1 regulates gastric emptying and feelings of satiety in the brain1,7

Brain

GIP activity7,‡

Reduced food intake

GLP-1 activity5,7

Reduced food intake

Increased satiety

Subcutaneous white adipose tissue

GIP activity3,7

Increased insulin sensitivity

Pancreas

GIP activity8

Increased insulin secretion

Increased glucagon in a glucose-dependent way

GLP-1 activity8

Increased insulin secretion

Reduced glucagon secretion

Stomach

GLP-1 activity6

Delayed gastric emptying

These pharmacodynamic effects of Mounjaro® were demonstrated based on a series of pre-clinical and/or clinical pharmacology animal studies.

Mounjaro® may have several effects on the body that help
support weight reduction in people living with obesity1,9:

*The effect on food intake during ad libitum lunch and dinner, appetite, food preference and craving were investigated in a 18 week blinded phase 1 study, 55 people with obesity undergoing caloric restriction were randomized 1:1 to Mounjaro® 15mg or placebo. Food cravings and preferences were measured with the Food Craving Inventory (FCI) and Food Preference Questionnaire (FPQ) at baseline, 8 week and 18 week. Mounjaro® significantly decreased food preference scores in 10 of 12 FPQ metrics at 8 week and 18 week compared to placebo. Mounjaro® significantly decreased the overall FCI score and the sweets, carbohydrates and starches, and fast-food fats sub scores, but not the high fat and fruit and vegetable sub scores at 8 week and 18 week compared to placebo11

†Areas of the body such as the pancreatic α and β endocrine cells, heart, vasculature, immune cells (leukocytes), gut, and kidney.1

‡Demonstrated in preclinical trials.

Through the combined actions of GIP and GLP-1, Mounjaro® lowers body weight with greater fat mass loss than lean mass loss1

GIP = Glucose-dependent insulinotropic polypeptide; GLP-1 = glucagon-like peptide-1

  1. Mounjaro® Hong Kong Prescribing Information
  2. Willard FS, et al. JCI Insight. 2020;5(17):e140532.
  3. Samms RJ, et al. Trends Endocrinol Metab. 2020;31(6):410-21.
  4. Roh E, Choi KM. Int J Mol Sci. 2023;24(4):3384.
  5. Drucker DJ. Mol Metab. 2022;57:101351.
  6. Holst JJ, et al. Br J Pharmacol. 2022;179(4):727-42.
  7. Nauck MA, et al. Diabetes Obes Metab. 2021;23(Suppl 3):5-29.
  8. Theilade S, et al. Diabetes Obes Metab. 2021;23(Suppl 1):17-35.
  9. Martin CK, et al. Diabetes. 2023;72(Suppl 1)128-OR.
  10. Jastreboff AM, et al. N Engl J Med. 2022;387(3):205-16.
  11. Martin CK, et al. Diabetes. 2023;72(suppl):128-OR

What kind of weight reduction could be achieved with Mounjaro®?

With Mounjaro®, results seen as soon as 4 weeks and continued through 72 weeks1,2,†

SURMOUNT-1 was a Phase 3, multicenter, randomized, placebo-controlled, double-blinded clinical trial investigating the efficacy and safety of 5 mg, 10 mg, and 15 mg Mounjaro® administered once weekly subcutaneously compared with placebo for weight management as an adjunct to a reduced-calorie diet and increased physical activity, in participants who have obesity, or overweight with weight-related complications (excluding T2D). 2 All randomized participants were planned to undergo a 72-week treatment period. 2 After the 72-week treatment period, participants without prediabetes (at randomization) proceeded to a four-week safety follow-up, while those with prediabetes (at randomization) continued in an additional two-year study treatment period. 2

SURMOUNT-1 study design

†p<0.001 vs baseline. Mean % change in weight vs baseline (co-primary endpoint) at 72 weeks was -16.0% and -21.4% for the 5 mg and 10 mg doses respectively. Mean % change in weight vs placebo at 72 weeks was -13.5%, -18.9%, -20.1% for the 5 mg, 10 mg, and 15 mg doses respectively (p<0.001 vs placebo, adjusted for multiplicity).1,2

In the SURMOUNT-1 study, Mounjaro® led to greater weight reductions compared to placebo.1,2,^,†,‡

Percentage change in body weight over time from baseline to Week 721,2

^Studied in adults with obesity (BMI of ≥30 kg/m2) or overweight (BMI of ≥27 kg/m2) with at least one weight-related complication, excluding T2D.2 All participants received lifestyle interventions, including a reduced-calorie diet and increased physical activity.2

†Efficacy estimand, MMRM analysis, mITT population (efficacy analysis set).2

‡p<0.001 vs baseline. Mean % change in weight vs baseline was a co-primary endpoint at 72 weeks. Mean % change in weight vs placebo at 72 weeks was -13.5%, -18.9%, -20.1% for the 5 mg, 10 mg and 15 mg doses respectively (p<0.001 vs placebo, adjusted for multiplicity). Mean kg change in weight vs placebo at week 72 was -13.8 kg, -19.8 kg, -21.2 kg for the 5 mg, 10 mg and 15 mg doses respectively (p<0.001 vs placebo, not adjusted for multiplicity).1,2

*Hypothetical patient profile

In the SURMOUNT-1 study, up to 96% of people taking Mounjaro® achieved a clinically significant weight reduction of ≥5% but some achieved even greater reductions in body weight.²,‡,§ Mounjaro® also helped more than 6 out of 10 living with obesity achieve a ≥20% weight reduction.2

Percentage of people who achieved ≥20% and ≥25% weight reduction at 72 weeks1,2,#,†

#Studied in adults with obesity (BMI of ≥30 kg/m2) or overweight (BMI of ≥27 kg/m2) with at least one weight-related complication, excluding T2D.2 All participants received lifestyle interventions, including a reduced-calorie diet and increased physical activity.2

†Efficacy estimand, MMRM analysis, mITT population (efficacy analysis set).2

‡p<0.001 vs placebo, not adjusted for multiplicity.1

§p<0.001 vs placebo, adjusted for multiplicity.1

Exploratory endpoint, hypothesis testing was not conducted.2

*Hypothetical patient profile

People taking Mounjaro® experienced improvements in body composition1,2

People treated with Mounjaro® had a reduction in total body fat mass ~3x greater than the reduction in lean mass, resulting in improvement in body composition.1,2

*Hypothetical patient

Percentage change in body composition (DEXA) compared to placebo1-3,^,†,‡

^Studied in adults with obesity (BMI of ≥30 kg/m2) or overweight (BMI of ≥27 kg/m2) with at least one weight-related complication, excluding T2D.2 All participants received lifestyle interventions, including a reduced-calorie diet and increased physical activity.2

†p<0.001 vs placebo.

‡n=160. Mounjaro® pooled 5, 10, and 15 mg groups, efficacy estimand. ANCOVA analysis, and data presented are least squares means ± standard errors.2

ANCOVA = analysis of covariance; BMI = body mass index; DEXA = dual-energy X-ray absorptiometry; mITT = modified intent-to-treat; MMRM = mixed model for repeated measures; QW = once weekly; T2D = type 2 diabetes

  1. Mounjaro®. Hong Kong Prescribing Information.
  2. Jastreboff AM, et al. N Engl J Med. 2022;387(3):205-16 (+Suppl. Appendix).
  3. Jastreboff AM. Presentation. 58th EASD Congress Sweden2022 [Cited 21 December 2023]. Available from URL: https://www.practiceupdate.com/content/easd-2022-substantial-weight-reduction-with-tirzepatide-produces-multiple-beneficial-metabolic-effects/142614.
  4. Samms RJ, et al. Trends Endocrinol Metab. 2020;31(6):410-21.

What other benefits could be achieved with Mounjaro®?

Cardiometabolic improvements demonstrated in key parameters in people living with obesity1,2,#

In the SURMOUNT-1 study, Mounjaro® led to improvements in blood pressure, blood lipids and waist circumference in people living with obesity compared with placebo.1,2

Improvements in key cardiometabolic parameters from baseline to 72 weeks1,2,*
Insulin sensitivity and insulin secretion improvements were demonstrated with Mounjaro® 15 mg

*Studied in adults with obesity (BMI of ≥30 kg/m2) or overweight (BMI of ≥27 kg/m2) with at least one weight-related complication, excluding T2D.2 All participants received lifestyle interventions, including a reduced-calorie diet and increased physical activity.2

†Averages from each dosage group are the least-squares mean changes from baseline. Statistical tests were done for each dosage group, not the ranges from groups.2

‡Exploratory endpoint, Mounjaro® is not indicated for reversion to normoglycaemia

§Hyperinsulinemic euglycemic clamp study in patients with T2D.1

Hyperglycemic clamp study in patients with T2D.1

#Mounjaro® is not indicated to reduce cardiometabolic parameters. In SURMOUNT-1 trial, reductions in blood pressure, waist circumference, triglycerides, HDL cholesterol and LDL cholesterol were secondary endpoints.1

BMI = body mass index; HDL = High-density lipoprotein; LDL = low-density lipoprotein; T2D = type 2 diabetes

  1. Mounjaro® Hong Kong Prescribing Information
  2. Jastreboff AM, et al. N Engl J Med. 2022;387(3):205-16 (+Suppl. Appendix).

Should Andrea* expect any AEs when she gets started with Mounjaro®?

In the SURMOUNT-1 trial, Mounjaro® had a similar safety profile to other incretin-based therapies1,2,^

The most common adverse events with Mounjaro® were gastrointestinal in nature and were mostly mild to moderate.1,2

Gastrointestinal adverse events primarily occurred during dose escalation and decreased over time.1,2

Adverse events occurring in at least 5% of participants taking Mounjaro® 2,^
Percentage of participants who discontinued treatment2,^

^Studied in adults with obesity (BMI of ≥30 kg/m2) or overweight (BMI of ≥27 kg/m2) with at least one weight-related complication, excluding T2D.2 All participants received lifestyle interventions, including a reduced-calorie diet and increased physical activity.2

†All participants in the clinical trial received Mounjaro and autoinjector pen.

*Hypothetical patient profile

AEs = adverse events; BMI = body mass index; GI = gastrointestinal; T2D = type 2 diabetes

  1. Mounjaro® Hong Kong Prescribing Information
  2. Jastreboff AM, et al. N Engl J Med. 2022;387(3):205-16 (+Suppl. Appendix).

How can Mounjaro® be individualized based on unique needs?

Get your patients started on their
journey with Mounjaro®

Mounjaro® offers personalized, once-weekly dosing1

*Hypothetical patient
Watch a demonstration of how Mounjaro® should be used
Watch Video
Fat Accumulation and Associated Adipocyte Dysfunction are the Key Drivers of weight-related complications1-4

IL-6 = interleukin-6; MCP-1 = monocyte chemoattractant protein-1; TNF-a = tumor necrosis factor alpha

  1. Longo M, et al. Int J Mol Sci. 2019;20(9):2358
  2. Samms RJ, et al. Trends Endocrinol Metab. 2020;31(6):410-21.
  3. Bray GA, et al. Obes Rev. 2017;18(7):715-23.
  4. Guglielmi V, et al. J Diabetes Endocrinol Metab Disord. 2017;1(1)1-6.
  1. Mounjaro® Hong Kong Prescribing Information

I can't remember the last time I was this optimistic about reaching my weight loss goal.

– Andrea*

^Mounjaro® is not indicated to reduce cardiometabolic parameters. In SURMOUNT-1 trial, reductions in blood pressure, waist circumference, triglycerides, HDL cholesterol and LDL cholesterol were secondary endpoints.1

†Studied in adults with obesity (BMI of ≥30 kg/m2) or overweight (BMI of ≥27 kg/m2) with at least one weight-related complication, excluding T2D.2 All participants received lifestyle interventions, including a reduced-calorie diet and increased physical activity.2

‡p<0.001 vs baseline. Mean % change in weight vs baseline (co-primary endpoint) at 72 weeks was -16.0% and -21.4% for the 5 mg and 10 mg doses respectively. Mean % change in weight vs placebo at 72 weeks was -13.5%, -18.9%, -20.1% for the 5 mg, 10 mg and 15 mg doses respectively (p<0.001 vs placebo, adjusted for multiplicity).1,2

*Hypothetical patient image and profile

BMI = body mass index; GIP = Glucose-dependent insulinotropic polypeptide; GLP-1 = glucagon-like peptide-1; HDL = high-density lipoprotein; LDL: Low-density lipoprotein; T2D = type 2 diabetes

  1. Mounjaro® Hong Kong Prescribing Information
  2. Jastreboff AM, et al. N Engl J Med. 2022;387(3):205-16 (+Suppl. Appendix).
  3. Willard FS, et al. JCI Insight. 2020;5(17):e140532.

INDICATION1
Mounjaro® is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:
- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
- in addition to other medicinal products for the treatment of diabetes

For weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial Body Mass Index (BMI) of
- ≥30 kg/m2 (obesity) or
- ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g. hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus)

SAFETY PROFILE1
Type 2 diabetes mellitus:
In 7 completed phase 3 studies, 5119 patients were exposed to Mounjaro(r) alone or in combination with other glucose lowering medicinal products. The most frequently reported adverse reactions were gastrointestinal disorders, including nausea (very common), diarrhoea (very common), constipation (common), and vomiting (common). In general, these reactions were mostly mild or moderate in severity and occured more often during dose escalation and decreased over time.
Weight management:
In 2 completed phase 3 studies, 2519 patients were exposed to Mounjaro(r) alone or in combination with other glucose lowering medicinal products. The most frequently reported adverse reactions were gastrointestinal disorders, including nausea (very common), diarrhoea (very common), constipation (very common), and vomiting (very common). In general, these reactions were mostly mild or moderate in severity and occured more often during dose escalation and decreased over time.

Disclaimer
This is an advertorial materials, published and distributed through unrestricted support from Eli Lilly Asia Inc., for the purpose of continuing medical education only. The views expressed in this publication reflect the experience and/or opinion of the author(s) and are not necessarily those of editors and publisher. Because of rapid advances in medicine, independent verification of clinical diagnoses, medical suitability and dosage should be made before treatment prescription.
Terms of use Privacy statement
Copyright ©2024-2025 Omnihealth Practice. All rights reserved.